Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DVAX 
Dynavax Technologies Corporation (DVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: DVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.8
1 Year Target Price $22.8
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.11% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10B USD | Price to earnings Ratio - | 1Y Target Price 22.8 |
Price to earnings Ratio - | 1Y Target Price 22.8 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 9.22 - 14.63 | Updated Date 09/14/2025 |
52 Weeks Range 9.22 - 14.63 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.67% | Operating Margin (TTM) 17.45% |
Management Effectiveness
Return on Assets (TTM) 0.52% | Return on Equity (TTM) -9.28% |
Valuation
Trailing PE - | Forward PE 29.24 | Enterprise Value 775256005 | Price to Sales(TTM) 3.49 |
Enterprise Value 775256005 | Price to Sales(TTM) 3.49 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA 30.92 | Shares Outstanding 117267000 | Shares Floating 100973165 |
Shares Outstanding 117267000 | Shares Floating 100973165 | ||
Percent Insiders 0.6 | Percent Institutions 97.97 |
Upturn AI SWOT
Dynavax Technologies Corporation
Company Overview
History and Background
Dynavax Technologies Corporation was founded in 1996. Initially focused on immunostimulatory sequences (ISS) technology, Dynavax has evolved into a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines.
Core Business Areas
- Hepatitis B Vaccines: Dynavax's primary focus is on its hepatitis B vaccine, HEPLISAV-B, designed for adult protection. They also explore other vaccine development and commercialization opportunities.
Leadership and Structure
Ryan Spencer serves as the Chief Executive Officer. The company has a typical corporate structure with executive leadership and functional departments.
Top Products and Market Share
Key Offerings
- HEPLISAV-B: HEPLISAV-B is a hepatitis B vaccine for adults. Market share data fluctuates, but it has gained significant traction as a two-dose vaccine compared to the traditional three-dose vaccines. Competitors include GSK (Engerix-B and Twinrix) and Merck (Recombivax HB). Revenue information will be included in Financial Performance.
Market Dynamics
Industry Overview
The vaccine industry is a large and growing market driven by the need to prevent infectious diseases. It's characterized by intense competition, high regulatory hurdles, and significant R&D investment.
Positioning
Dynavax is positioned as a key player in the hepatitis B vaccine market with HEPLISAV-B, offering a more convenient dosing schedule. They compete with established pharmaceutical giants.
Total Addressable Market (TAM)
The global hepatitis B vaccine market is projected to reach billions of USD. Dynavax is well-positioned to capture a significant portion of this TAM with HEPLISAV-B.
Upturn SWOT Analysis
Strengths
- HEPLISAV-B's superior efficacy and two-dose regimen
- Strong commercialization strategy
- Proprietary adjuvant technology (CpG 1018)
Weaknesses
- Reliance on a single key product (HEPLISAV-B)
- Competition from established players
- Manufacturing and supply chain risks
Opportunities
- Expanding HEPLISAV-B's market share
- Developing new vaccines using CpG 1018 adjuvant
- Strategic partnerships and acquisitions
Threats
- Competition from existing and new vaccines
- Adverse events impacting vaccine acceptance
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Merck (MRK)
Competitive Landscape
Dynavax's HEPLISAV-B has advantages (two dose) but competes with established brands and distribution networks of larger companies like GSK and Merck. Dynavax is heavily focused on the Adult segment of Hepatitis B vaccines.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by the increasing sales and adoption of HEPLISAV-B.
Future Projections: Future growth projections depend on HEPLISAV-B market penetration and potential new vaccine development.
Recent Initiatives: Focus on expanding HEPLISAV-B reach, potential new vaccine development programs using their adjuvant technology.
Summary
Dynavax is a promising biopharmaceutical company with HEPLISAV-B as its primary revenue driver. The two-dose advantage is proving successful. Reliance on a single product poses a risk. Expansion of its pipeline through development and potential partnerships will be crucial for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data and financial figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dynavax Technologies Corporation
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2004-02-19 | CEO & Director Mr. Ryan Spencer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 405 | Website https://www.dynavax.com |
Full time employees 405 | Website https://www.dynavax.com | ||
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.